Glutation y Rainauds ( Raynauds)
References
1. Raynaud A.G.M. 1862 De l’asphyxie locale et de la gangrène symétrique des extrémités. Doctoral thesis. L. Leclerc, Libraire-Éditeur Paris, English translation by Thomas Barlow In Selected Monographs, New Sydenham Society, London 1888, p. 1.
2. Dowd P., Burnstock G., Marshall I., Bull H.A., Foreman J., Goldsmith P., 1996. Raynaud’s phenomenon. Lancet 346:283.
3. Failli P., Palmieri L., D’Alfonso C., Giovannelli L., Generini S., Del Rosso A., Pignone A., Stanflin N., Orsi S., Zilletti L., Matucci-Cerinic M., 2002. Effect of N-acetyl-L-cysteine on peroxynitrite and superosside anion production of lung alveolar macrophages in systemic sclerosis. Nitric Oxide 7:277.
4. Bisseling T.M., Roes E. Maria, Makers M.T. Raij, Steegers E.A., Peters W.H., Smits P., 2004. N-acetylcysteine restores nitric oxide-mediated effects in the fetoplacental circulation of preeclamptic patients. Am. J. Obstet. Gynecol. 191:328.
5. Schaser K.-D., Bail H. J., Scchewior L., Stover J.F., Melcher I., Haas N.P., Mittlmeier T., 2005. Acute effects of N-acetylcysteine on skeletal muscle microcirculation following closed soft tissue trauma in rats. J. Orthop. Res. 23:231.
6. Sambo P., Amico D., Giacomelli R., Matucci-Cerinic M., Salsano F., Valentini G., Gabrielli A., 2001. Intravenous N-Acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: A pilot study. J. Rheumatol. 28:2257.
7. Merla A., Romani G.L., Di Luzio S., Di Donato L., Farina G., Proietti M., Pisarri S., Salsano F., 2002. Raynaud’s phenomenon: Infrared functional imaging applied to diagnosis and drug effects. Int. J. Immunopathol. Pharmacol. 15:41.
8. Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., Eto T., 1993. Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun. 192:553.
9. Eto T. 2001. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides 22:1693.
10. Sugo S, Minamino N., Shoji H., Kangawa K., Kitamura K., Eto T., Matsuo H., 1995. Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 207:25.
11. Clark S, Campbell F., Moore T., Jayson M.I.V., King T.A., Herrick A.L., 1999. Laser Doppler Imaging- a new technique for quantifying microcirculatory flow in patients with primary Raynaud’s phenomenon and Systemic Sclerosis. Microvasc. Res. 57:284.
12. Letizia C., Cerci S., Centanni M., Scavo D., 1998. Circulating levels of adrenomedullin in patients with Addison’s disease before and after corticosteroid treatment. Clin. Endocrinol. 48:145.
13. Fung H.L., Chong S., Kovaluc E., Hough K., Kakemi M., 1988. Mechanisms for the pharmacologic interaction of organic nitrates with thiols: Existence of an extracellular pathway for the reversal of nitrate vascular tolerance by N-Acetylcysteine. J. Pharmacol. Exp. Ther. 345:524.
14. Feelisch M., Noach E.A., 1987. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur. J. Pharmacol. 139:19.
15. Ignarro L.J. 1989. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ. Res. 65:1.
16. Aruoma O.I., Halliwell B., Hoey B.M., Butler J., 1989. The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic. Biol. Med. 6:593.
17. Ignarro L.J., Lippton H., Edwards J.C., Baricos W.H., Hyman A.L., Kadowitz P.J., et al., 1981. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates. J. Pharmacol. Exp. Ther. 218:739.
18. Chun T.H., Itoh H., Saito T., Yamahara K., Doi K., Mori Y., Ogawa Y., Yamashita J., Tanaka T., Inoue M., Masatsugu K., Sawada N., Fukunaga Y., Nakao K., 2000. Oxidative stress augments secretion of endothelium-derived relaxing peptides, C-type natriuretic peptide and adrenomedullin. J. Hypertens. 18:575.
19. Sugo S., Minamino N., Shoji H., Kangawa K., Matsuo H., 1995. Effects of vasoactive substances and camp related compounds on adrenomedullin production in cultured vascular smooth muscle cells. FEBS Lett. 369:311.
20. Ichiki Y., Kitamura K., Kangawa K., Kawamoto M., Matsuo H., Eto T., 1994. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett. 338:6.
21. Ishiyama Y., Kitamura K., Ichiki Y., Nakamura S., Kida O., Kangawa K., Eto T., 1993. Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur. J. Pharmacol. 241:271.
22. Isumi Y., Kubo A., Katafuchi T., Kangawa K., Minamino N., 1999. Adrenomedullin suppresses interleukin-1beta-induced tumor necrosis factor-alpha production in Swiss 3T3 cells. FEBS Lett. 463:110.
23. Letizia C., Danese C., D’Erasmo E., 1999. Increased plasma adrenomedullin concentrations in patients with Raynaud’s phenomenon. J. Rheumatol. 26:759.
24. Ueda S., Nishio K., Minamino N., Kubo A., Akai Y., Kangawa K., Matsuo H., Fujimura Y., Yoshioka A., Masui K., Doi N., Murao Y., Miyamoto S., 1999. Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am. J. Respir. Crit. Care Med. 160:132.
25. Nanke Y., Kotake S., Akama H., Shimamoto K., Hara M., Kamatani N., 2000. Raised plasma adrenomedullin in patients with systemic sclerosis complicated by pulmonary hypertension. Ann. Rheum. Dis. 59:493.
26. Vizza C.D., Letizia C., Sciomer S., Naeije R., Della Rocca G., Di Roma A., Musaro S., Quattrucci S., Gaudio C., Battagliese A., Badagliacca R., D’Erasmo E., Fedele F., 2004. Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease. Regul. Pept. 124:187.
27. Kahaleh M.B. 1991. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum. 34:978.
28. Takahashi K., Yoshinoya A., Murakami O., Totsune K., Shibahara S., 2000. Production and secretion of two vasoactive peptides, adrenomedullin and endothelin-1, by cultured human adrenocortical carcinoma cells. Peptides 21:251.
29. Horio T., Kohno M., Kano H., Ikeda M., Yasunari K., Yokokawa K., Minami M., Takeda T., 1995. Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells. Circ. Res. 77:60.
30. Yanagisawa M., Kurihara H., Kimura S., Goto K., Masaki T., 1988. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J. Hypertens. 6(S): 188–91.
31. Redondo P., Subira M.L., 1996. N-Acetylcysteine inhibits production of TNFα and IL-1β. Arch. Intern. Med. 156:1238.
32. Cassano N., Loconsole F., Amoruso A., Coviello C., Filieri M., Filotico R., Grandolfo M., Vena G.A., 2004. Infliximab monotherapy for refractory psoriasis: Preliminary results. Int. J. Immunopathol. Pharmacol. 17:373
33. Franchi C., Cainelli G., Frigerio E., Garutti C., Altomare G.F., 2004. Association of Cyclosporine and 311 nm UVB in the treatment of moderate to severe forms of psoriasis: A new strategic approach. Int. J. Immunopathol. Pharmacol. 17:401.